- Home
- INVA vs KRSA Comparison
INVA vs KRSA Comparison
Compare INVA & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | KRSA |
|---|---|---|
| Founded | 1996 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INVA | KRSA |
|---|---|---|
| Price | $20.62 | $31.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $35.00 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 619.0K | 112.3K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | 8.26 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $217,217,000.00 | $2,074,000.00 |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | $16.86 | ★ N/A |
| Revenue Growth | ★ 62.63 | 3.70 |
| 52 Week Low | $17.45 | $29.03 |
| 52 Week High | $25.15 | $37.27 |
Technical Indicators
Market Signals| Indicator | INVA | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 45.24 |
| Support Level | $20.40 | $29.98 |
| Resistance Level | $21.69 | $36.30 |
| Average True Range (ATR) | 0.47 | 2.56 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 9.60 | 34.98 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About KRSA Korsana Biosciences Inc. Common Stock
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.